RION has formed INTENT Biologics, a new independent biotechnology company focused exclusively on developing the first-in-class exosome therapies for Inflammation and Immunology (I&I). INTENT Biologics launches with exclusive and perpetual worldwide rights to RION’s Purified Exosome Product (PEP) biologic platform in I&I, and will advance PEP Biologic into Phase-III clinical development for advanced tissue regeneration and immune-mediated dermatologic indications.

In addition to it, Suneet Varma has been appointed as the Chief Executive Officer (CEO) of INTENT Biologics. Varma brings over 30 years of global biopharma leadership, including his tenure as Global President of Pfizer Oncology and Rare Diseases and recent service on the Board of Directors at Cerevel Therapeutics.

“Creation of INTENT Biologics marks a pivotal milestone in our mission to revolutionise standards of care through regenerative exosome science. By creating a company with dedicated focus on deploying our exosome platform in I&I, we can accelerate the clinical and commercial path for PEP Biologic and unlock its potential across multiple high-impact indication,” said Atta Behfar, MD, PhD, Co-Founder, RION.

INTENT Biologics leverages RION’s proprietary and platelet-derived exosome biomanufacturing platform to produce PEP Biologic at clinical and commercial scale. Packaged as a shelf-stable lyophilised powder, each dose contains regenerative exosomes designed to deliver polyvalent biologic signals that reduce inflammation, regulate immune responses and promote tissue regeneration.

“INTENT Biologics is uniquely positioned to redefine therapeutic approaches in Inflammation and Immunology with a novel mechanism of action that harnesses regenerative exosomes to restore immune balance and reduce inflammation which, in turn, promotes optimal healing across many diseases and patient subpopulations. With a USD 30B+ market opportunity and a highly de-risked clinical path, we are poised to rapidly advance PEP Biologic into late-stage pivotal trials,” said Suneet Varma, CEO, INTENT Biologics.